Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

Rheumatology

Volumn 40, Issue 2, 2001, Pages 205-211

  Edwards, J C W ^a,b   Cambridge, G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Rheumatology Unit   (United Kingdom)

Author keywords

Anti CD20; Autoimmunity; B lymphocyte; Rheumatoid arthritis; Rituximab

Indexed keywords

ANTIBIOTIC AGENT; CD20 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; MONOCLONAL ANTIBODY; PREDNISOLONE; RHEUMATOID FACTOR; RITUXIMAB; STEROID;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FOLLOW UP; HUMAN; HYPOTHESIS; LYMPHOCYTE DEPLETION; MALE; PRIORITY JOURNAL; RELAPSE; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; ROSACEA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0035093233     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/40.2.205     Document Type: Article

References (29)

1. Rheumatoid arthritis: A disease of T lymphocyte-macrophage immunoregulation
2. Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis
3. Oncogenes in rheumatoid arthritis
4. IgG rheumatoid factors and self association of these antibodies
5. Is rheumatoid factor relevant
6. Rheumatoid arthritis: Cell and tissue pathology
7. Variable region gene usage of human monoclonal rheumatoid factors derived from healthy donors following immunization
8. Human rheumatoid factor production is dependent on CD40 signaling and autoantigen
9. The structure and origin of rheumatoid factors
10. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells
11. Rheumatoid arthritis: The predictable effect of small immune complexes in which antibody is also antigen
12. Do self-perpetuating B lymphocytes drive human autoimmune disease
13. The CD19/CR2/TAPA-1 complex of B lymphocytes: Linking natural to acquired immunity
14. Gamma globulin complexes in synovial fluids of patients with rheumatoid arthritis
15. Human complement activation by self-associated IgG rheumatoid factors
16. Rheumatoid factor stereochemistry analysed by real space modelling
17. Induction of tumour necrosis factor alpha production by human monocytes: A key role for FcγRIIIa in rheumatoid arthritis
18. Differential distribution of FcgRIIIa in normal human tissues
19. Expression of molecules involved in B lymphocyte survival and differentiation by synovial fibroblasts
20. The ability of synoviocytes to support terminal differentiation of activated B cells may explain plasma cell accumulation in rheumatoid synovium
21. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
22. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
23. Humanised monoclonal antibody therapy for rheumatoid arthritis
24. Autologous hematopoietic stem cell transplantation in refractory rheumatoid arthritis
25. A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis
26. Intensified-dose cyclophosphamide and granulocyte-stimulating factor administration for haematopoietic stem cell mobilization in refractory rheumatoid arthritis
27. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis
28. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
29. Entanercept therapy in therapy for rheumatoid arthritis